

(<https://www.aphadruginfoline.com>)

[Home](#) > Biosimilar to trastuzumab approved for patients with HER2-overexpressing breast cancer

---

Generic Name:

Trastuzumab-pkrb

Trade Name:

Herzuma

Company:

Celltrion

Notes:

FDA approved [trastuzumab-pkrb](#), a [HER2/neu receptor antagonist](#), as a biosimilar to trastuzumab (Herceptin) for patients with HER2-overexpressing breast cancer.

Common expected adverse effects include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough, and rash. Serious expected adverse include worsening of chemotherapy-induced neutropenia.

Like trastuzumab, the labeling for [trastuzumab-pkrb](#) contains a boxed warning to alert health professionals and patients about increased risks of cardiomyopathy, infusion reactions, pulmonary toxicity, and embryo-fetal toxicity.

Medication Monitor Categories:

[Supplemental Approvals](#)

---

**Source URL:** <https://www.aphadruginfoline.com/supplemental-approvals/biosimilar-trastuzumab-approved-patients-her2-overexpressing-breast-cancer>